Neurocrine Biosciences, Inc. (NBIX) Q2 2013 Earnings Results

Neurocrine Biosciences Beats on EPS, Stock Up 1.16%

Neurocrine Biosciences reported a narrower-than-expected loss per share, which led to a positive stock reaction, rising by 1.16%. The company did not provide revenue figures or future guidance, leaving some uncertainty. Investors may be encouraged by the EPS beat, suggesting better-than-anticipated cost management or operational efficiency.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$-0.18	N/A	+8.16%
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Cautiously Optimistic

Management expressed satisfaction with the EPS results, highlighting their commitment to pipeline development. They remain focused on long-term growth.

We are pleased with our EPS performance this quarter.

Our focus remains on advancing our pipeline.

Neurocrine Biosciences Beats on EPS, Stock Up 1.16%

Key numbers

Management commentary

Neurocrine Biosciences, Inc.

More earnings this week

Neurocrine Biosciences Beats on EPS, Stock Up 1.16%

Key numbers

Management commentary